Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - Featuring Eli Lilly & Company, Amgen, Johnson & Johnson, and Aclaris Therapeutics Among Others
08 avr. 2024 10h42 HE
|
Research and Markets
Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034: Market By Drug Class; By Application; and By Region" report has been...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
23 févr. 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16 févr. 2024 00h59 HE
|
Regeneron Pharmaceuticals, Inc.
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25 janv. 2024 14h29 HE
|
Regeneron Pharmaceuticals, Inc.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
Global Dermatology Drugs Market 2024-2034: Growth Accelerated by Surging Skin Disease Prevalence, New Product Launches, Robust R&D, Clinical Studies, Therapeutic Drug Approvals, Collaborative Innovations
25 janv. 2024 06h39 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatology Drugs Market Analysis & Forecast 2024-2034: By Application; By Route of Administration; By Distribution Channel; and By Region"...
DUPIXENT Drug Insights and Market Forecasts, 2032
01 déc. 2023 06h23 HE
|
Research and Markets
Dublin, Dec. 01, 2023 (GLOBE NEWSWIRE) -- The "DUPIXENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.DUPIXENT's potential as a game-changer...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
15 août 2023 15h40 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
Global Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBio
12 août 2021 04h58 HE
|
Research and Markets
Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This 'Netherton...
Global $34.5 Billion Dermatology Drugs Market Analysis and Growth Forecast to 2030
16 mars 2021 06h58 HE
|
Research and Markets
Dublin, March 16, 2021 (GLOBE NEWSWIRE) -- The "Dermatology Drugs Market Research Report: By Treatment, Drug, Prescription Mode, Therapy Area, Distribution Channel, End User - Global Industry...